Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 24-month, Phase IV, Randomized, Double Masked, Multi-center Study of Ranibizumab Monotherapy or Ranibizumab in Combination With Verteporfin Photodynamic Therapy on Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy

Next Previous
Search
Trial Profile

A 24-month, Phase IV, Randomized, Double Masked, Multi-center Study of Ranibizumab Monotherapy or Ranibizumab in Combination With Verteporfin Photodynamic Therapy on Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Verteporfin (Primary) ; Ranibizumab
  • Indications Polypoidal choroidal vasculopathy
  • Focus Therapeutic Use
  • Acronyms EVEREST II
  • Sponsors Novartis

    • Most Recent Events

    • 01 Nov 2022 Results published in the Retina
    • 01 Nov 2017 Primary endpoint (Complete polyp regression assessed by ICGA at Month 12) has been met, as per results published in the JAMA Ophthalmology.
    • 01 Nov 2017 Primary endpoint (Change from Baseline in in Visual Acuity (Letters) of the Study Eye to Month 12) has been met, as per results published in the JAMA Ophthalmology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top